; The Flow Cytometry Shared Service (FCSS) at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) offers flow cytometry equipment and technical expertise to UMGCC members conducting research in cancer biology and other areas of basic and applied science. Services are open to the entire University of Maryland campus, but UMGCC accounts for about 75 percent of the total use. FCSS provides full scale, state-of-the-art flow cytometry services, from functional and phenotypic analysis to cell sorting. Analytical instruments include a modern, fully digital, 3-laser Becton Dickinson (BD) LSR II flow cytometer, and two analog flow cytometers: a BD LSR 1 and a BD FACScan instrument. Cell sorting is conducted with (1) a BD FACSAria I digital instrument equipped with two lasers and seven-colordetection capability and (2) a BD FACSVantage SE instrument upgraded with BD's Digital Acquisition System (DIVA) and equipped with three lasers including a tunable krypton laser for 351 nm ultraviolet excitation. FCSS also offers users both operator-assisted and self-service data analysis on several platforms as well as experimental training and consultation to support project design for individual analytical or sorting experiments. The effectiveness of FCSS is evident from the steady increase of its utilization in recent years, the more than 50 principal investigators who are using the shared service, and the number of publications and National Cancer Institute-funded projects supported by experiments conducted with the help ofthe shared service. The goal of FCSS is to further increase the breadth and scope of its services by expanding cell-sorting capabilities;supporting novel, flow cytometry-based analytical applications;and strengthening cooperation with other UMGCC shared sen/ices to help introduce innovative, cutting-edge technologies to UMGCC investigators.
State-of-the-art fluorescent cell sorting and analytical flow-cytometry capabilities are indispensable to enhance our understanding of basic disease processes, ranging from stem cell biology to viral infections to cancer. The scientific objective of this facility is to provide flow cytometry services for investigators, in the Program in Oncology and campuswide, to assist them in achieving their scientific research goals.
|Appelt, Ane L; Vogelius, Ivan R; Pløen, John et al. (2014) Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys 90:110-8|
|Vogelius, Ivan R; Bentzen, Søren M (2014) Hypofractionated radiation therapy for prostate cancer: more food for thought from recent trial. J Clin Oncol 32:1852-3|
|Bao, Ting; Cai, Ling; Snyder, Claire et al. (2014) Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer 120:381-9|
|Barnett, Gillian C; Thompson, Deborah; Fachal, Laura et al. (2014) A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol 111:178-85|
|Bentzen, S M; Yarnold, J (2014) A toast to the silver anniversary of Clinical Oncology: a quarter of a century of advances in evidence-based radiation dose fractionation. Clin Oncol (R Coll Radiol) 26:599-601|
|Håkansson, Katrin; Specht, Lena; Aznar, Marianne C et al. (2014) Prescribing and evaluating target dose in dose-painting treatment plans. Acta Oncol 53:1251-6|
|Due, Anne K; Vogelius, Ivan R; Aznar, Marianne C et al. (2014) Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol 111:360-5|
|Song, Xiaomeng; Xia, Ronghui; Li, Jiang et al. (2014) Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma. Clin Cancer Res 20:701-10|
|Gojo, Ivana; Tan, Ming; Fang, Hong-Bin et al. (2013) Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res 19:1838-51|
|Natarajan, Karthika; Xie, Yingqiu; Burcu, Mehmet et al. (2013) Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PLoS One 8:e74653|
Showing the most recent 10 out of 18 publications